NLRP3 and Alzheimer disease: Recent studies have found that the effects of these medicine are mediated through NLRP3; for example, the protective effect of Epimedii folium and Curculiginis Rhizoma on AD has been regulated by the inhibitions of the NF-κB/mitogen-activated protein kinase (MAPK) pathway and the NLRP3 inflammasome (Lan et al., 2017).